Drug Profile
Research programme: 1,3-beta-glucan synthase inhibitors - Daiichi Sankyo
Alternative Names: Arborcandin CLatest Information Update: 13 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Cyclic peptides
- Mechanism of Action Cell wall inhibitors; Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 12 May 2003 Preclinical trials in Mycoses in Japan (unspecified route)